期刊文献+

氮唑类抗真菌药物研究进展 被引量:1

原文传递
导出
摘要 系统性真菌感染目前仍然是严重威胁人类健康的疾病,尽管在过去10年中,有多个新药上市,有氮唑类、棘白菌素类等,但是现有药物仍然存在着抗菌谱窄,毒副作用大,溶解度差,药代动力学性质不理想等缺点。本文对近10年来上市的抗真菌药物(氮唑类、棘白菌素类),处于各期临床研究阶段的抗真菌药物进行了综述。对仍在进行研究的抗真菌药物的新的作用靶点进行了总结,对抗真菌药物未来的发展方向进行了初步展望。
出处 《实用预防医学》 CAS 2011年第6期1172-1174,共3页 Practical Preventive Medicine
  • 相关文献

参考文献13

  • 1Pfaller M. A, Diekema D. J, Gibbs D. L, et al. Results from the AR- TEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5 - year analysis of susceptibilities of Candida species and other yeastspecies to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing[J]. J Clin Microbiol, 2007, 45 : 1735 - 1745.
  • 2Sable C. A, Strohmaier K. M, Chodakewitz J. A. Advances in antifun- gal therapy[J]. Annu Rev Meal, 2008, 59:361 - 379.
  • 3Messer S. A, Jones R. N, Fritsche T. R. International surveillance of Candida spp. and A_spergillus spp. : report from the SENTRY Antirni- crobial Surveillance Program (2003) [ J ]. J Clin Miembiol, 2006, 44 : 1782- 1787.
  • 4Marimon R, Serena C, Gene J ,et al. In vitro antiftmgal susceptibilities of five species of sporothfix[J]. Antimicrob Agents Chemother, 2008, 52 : 732 - 734.
  • 5Hof H. A new, broad- spectrum azole antifungaI: posaconazole- mechanisms of action and resistance, spectrum of activity[J]. Mycoses, 2006, 49(Suppl 1 ) :2 - 6.
  • 6Chau A. S, Mendrick C. A, Sabatelli F. J, et al. Application of real - time quantitative PCR to molecular analysis of C, andida albicans strains exhibiting reduced susceptibility to azoles[J ]. Antimicrob Agents Che- mother, 2004, 48:2124-2131.
  • 7Diekema D. J, Messer S. A, Holtis R. J, et al. Activities of caspofun- gin, itraconazole, tx3saconazole, ravuconazole, vorieonazole, and arn- photericin 13 against 448 recent clinical isolates of filamentous fungi[J]. J Clin Microbiol, 2003, 41:3623-3626.
  • 8Amyroudis N. G, Sutton D. A, Fothergill A. W, et al. In vitro suscep- tibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents[J]. Antimicrob Agents Chemother, 2007, 51 : 2587 2590.
  • 9Sobue S, Tan K, Shaw L, et al. Comparison of the pharmacokinetics of fosfluconazole and fluconazole after single intravenous administration of fosfluconazole in healthy Japanese and Caucasian volunteers [J ]. Eur J Clin Pharmacol, 2004, 60 : 247 - 253.
  • 10Ting P. C, Walker S. S. New agents to treat life- threatening ftwal nfection[J]. Gurr Top Med Ghem, 2008, 8- 592 - 602.

同被引文献12

引证文献1

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部